English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

P179 Neuroprotection has so far proved disappointing in acute  ischemic stroke. However, neither clinical nor biological cues of  ongoing neurotoxicity were provided in previous phase III trials. Thus  it remains unsettled whether faulty drug selection, inadequate  patients′ traits, or both, explain treatment failure. In 258 patients  with first ever acute hemispheric ischemic stroke we found that  admission plasma concentrations of glutamate &gt;200 μmol/L (OR, 26.1;  95%CI, 6.9 to 98.6), interleukin-6 &gt;21.5 pg/mL (OR, 14.9; 95%CI, 4.4  to 50.8), and GABA  5.0 μmol/mL in CSF (OR, 5.3; 95%CI, 1.5 to 18.5),  were sensitive and specific independent predictors of patients at  high-risk of early neurologic deterioration regardless of infarction  topography, size, and mechanism. Sensitivity and specificity values are  given in the table. Early neurologic deterioration is a harbinger of  impending poor outcome that in many instances we could forecast using  the aforementioned tests. As early neurologic deterioration most  commonly reflects those molecular events that neuroprotectants are  aimed to prevent, we advocate to include it as a primary end-point in  forthcoming neuroprotectant trials. We also contend to launch large and  expensive trials once smaller studies restricted to patients at  high-risk of early worsening have disclosed laboratory indications of  neuroprotection.

Neuroprotection for acute ischemic stroke: Who is most to blame for current failure ?